NRx Pharmaceuticals, Inc.

Summary NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ( NRx , the Company , we , us or our ) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia. NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (HOPE), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy. All of our current drug development activities are focused on drugs that enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. The Company has three lead drug candidates NRX-100, a preservative-free formulation of ketamine for intravenous infusion, a generic preservative-free formulation of ketamine (KETAFREE ), and NRX-101, an oral fixed dose combination of D-cycloserine (DCS) and lurasidone. KETAFREE , NRX-100 and NRX-101 are in the process of submission for Food and Drug Administration (FDA) approval as follows: 1. An Abbreviated New Drug Application (ANDA) for KETAFREE was filed, with priority review requested in September 2025. The FDA approved the suitability of NRx’s proposed strength.